4 active not recruiting, 2 unknown, 2 withdrawn, 1 completed. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Active not recruiting 4, Unknown 2, Withdrawn 2, Completed 1 |
| Phase 2 | 5 | Withdrawn 2, Active not recruiting 1, Recruiting 1, Unknown 1 |
Follow CD19 Positive: new trials by email Literature Review of CD19 Positive trials Research Report on CD19 Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL) Subcutaneous Blinatumomab - CD19 Positive, Mixed Phenotype Acute Leukemia (MPAL) | Phase 2 | Recruiting | West Virginia University | 78 | 2026-01-15 | 2026-04-13 |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - CD19 Positive, Mantle Cell Lymphoma | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-10-03 | 2020-01-29 | |
| Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leukemia Blinatumomab, Laboratory Biomarker Analysis, Pembrolizumab - CD19 Positive, Philadelphia Chromosome Positive | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 36 | 2019-08-02 | 2025-05-30 |
| CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma. XYF19 CAR-T cell, Cyclophosphamide, Fludarabine - Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory | Phase 1 | Unknown | Xijing Hospital | 40 | 2019-08-01 | 2019-07-30 |
| Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine - CD19 Positive, CD22 Positive | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2019-05-15 | 2023-08-21 | |
| Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 33 | 2017-10-20 | 2026-06-30 |
| CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - B Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 | Active not recruiting | Stanford University | 56 | 2017-09-01 | 2025-11-18 |
| CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia CD19 CAR-T cells, CD19 CAR-T cells with CRS suppression technology - Acute Lymphoblastic Leukemia, CD19 Positive | Phase 1 / Phase 2 | Unknown | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | 40 | 2017-07-01 | 2024-05-28 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2015-12-16 | 2022-06-30 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Neoplasm, Residual (4) · Burkitt Lymphoma (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Biphenotypic, Acute (2) · Lymphoma, B-Cell (2) · Lymphoma, Follicular (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Mantle-Cell (2) · Lymphoma, Non-Hodgkin (2) · Disease Progression (1) · Recurrence (1)
Hemic and Lymphatic Diseases (10) · Immune System Diseases (10) · Immunoproliferative Disorders (10) · Lymphatic Diseases (10) · Lymphoproliferative Disorders (10) · Neoplasms (10) · Neoplasms by Histologic Type (10) · Hematologic Diseases (8) · Leukemia (8) · Leukemia, Lymphoid (8) · Lymphoma (7) · Pathologic Processes (6) · Pathological Conditions, Signs and Symptoms (6) · Lymphoma, Non-Hodgkin (5) · Disease Attributes (4)
Cyclophosphamide (6) · fludarabine phosphate (4) · Immunotherapy, Adoptive (3) · blinatumomab (2) · fludarabine (2) · CT-P10 (1) · CTL019 chimeric antigen receptor (1) · Carmustine (1) · Cytarabine (1) · Disulfides (1) · Etoposide (1) · Filgrastim (1) · Granulocyte Colony-Stimulating Factor (1) · Immunoglobulin G (1) · Melphalan (1)
M.D. Anderson Cancer Center (3) · Stanford University (2) · City of Hope Medical Center (1) · Jonsson Comprehensive Cancer Center (1) · Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd (1) · West Virginia University (1) · Xijing Hospital (1)
United States (8) · China (2)
Ashkan Emadi, MD (1) · Crystal Mackall (1) · Jin S Im (1) · Katy Rezvani (1) · Lihua Budde (1) · Lori Muffly, MD, MS (1) · Partow Kebriaei (1) · Sarah Larson, MD (1) · Xiaowen Tang, PhD (1)
PMID 34515338, PMID 32929049, PMID 33235353, PMID 34312556, PMID 34889384, PMID 36105799, PMID 38968138, PMID 41671463
P30CA016672 (2)